Floatz Rating
B60/100
Confidence
Indicative
Sponsor
University of California, San Francisco
Modality
Other
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05924672CT.gov Efficacy of Ra-223 in PSMA PET Optimally Selected Patients | — | Active Not Recruiting | — | — | — |
NCT05383079CT.gov Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04489719CT.gov Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT04681144CT.gov A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety | — | Completed | — | — | — |
NCT04206319CT.gov Radium-223 in Biochemically Recurrent Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04281147CT.gov Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body | — | Completed | — | — | — |
NCT04037358CT.gov RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers | — | Completed | — | — | — |
NCT03574571CT.gov A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03062254CT.gov Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy | — | Completed | — | — | — |
NCT03093428CT.gov Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC | — | Completed | — | — | — |
Show 13 more trialsShow fewer
NCT02903160CT.gov Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) | — | Completed | — | — | — |
NCT03002220CT.gov Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status | — | Completed | — | — | — |
NCT02463799CT.gov Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC | — | Completed | — | — | — |
NCT02925702CT.gov PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223. | — | Unknown | — | — | — |
NCT02518698CT.gov Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population | — | Completed | — | — | — |
NCT02225704CT.gov Radium-223 in Combination With Enzalutamide | — | Completed | — | — | — |
NCT02346526CT.gov A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer | — | Completed | — | — | — |
NCT02135484CT.gov Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases | — | Completed | — | — | — |
NCT02199197CT.gov Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer | — | Completed | — | — | — |
NCT02097303CT.gov Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis | — | Completed | — | — | — |
NCT00748046CT.gov Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton | — | Completed | — | — | — |
NCT00337155CT.gov BAY88-8223, Dose Finding Study in Patients With HRPC | — | Completed | — | — | — |
NCT00459654CT.gov A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Radium Ra-223 (this asset) | University of California, San Francisco | P3 | B · 60 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Radium Ra-223
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P3 | BB · 70 |
| Castration-Resistant Prostate Carcinoma | — | P4 | BB · 70 |
| Metastatic Carcinoma In The Bone | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Radium Ra-223 in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/radium-ra-223-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →